Paragon Capital Boosts Stake in Halozyme Therapeutics

Institutional investor adds 18,920 shares to biotech portfolio in Q4

Apr. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, polished metal gears and machinery in shades of silver, bronze, and black, conceptually representing the complex financial infrastructure and institutional investment powering the biotech industry.Paragon Capital's strategic investment in Halozyme Therapeutics reflects the institutional backing fueling growth in the biotech sector.San Diego Today

Paragon Capital Management Inc. purchased a new stake of 18,920 shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to a recent 13F filing with the SEC. The investment, valued at approximately $1.27 million, expands Paragon's position in the biopharmaceutical company.

Why it matters

Halozyme Therapeutics is a leading biotech firm focused on drug delivery technologies, making this a notable investment by Paragon Capital as the firm looks to capitalize on the company's growth potential in the pharmaceutical space.

The details

The 18,920 shares purchased by Paragon Capital represent a new stake in Halozyme Therapeutics. Several other hedge funds and institutional investors also recently bought and sold HALO shares, including Empowered Funds LLC, Acadian Asset Management LLC, HSBC Holdings PLC, and EverSource Wealth Advisors LLC.

  • Paragon Capital made the investment during the fourth quarter of 2025.

The players

Paragon Capital Management Inc.

An institutional investment firm that purchased a new stake in Halozyme Therapeutics.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in drug delivery technologies, including its flagship ENHANZE platform.

Got photos? Submit your photos here. ›

The takeaway

Paragon Capital's investment in Halozyme Therapeutics signals confidence in the biotech firm's growth prospects and drug delivery innovations, underscoring the stock's appeal among institutional investors in the pharmaceutical space.